Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates

Bioanalysis

Volumn 3, Issue 6, 2011, Pages 677-700

  Stephan, Jean Philippe ^a   Kozak, Katherine R ^a   Wong, Wai Lee T ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTIBODY; ANTIBODY CONJUGATE; CALCEIN; CALICHEAMICIN; CANTUZUMAB MERTANSINE; CD74 ANTIBODY DOXORUBICIN CONJUGATE; GEMTUZUMAB OZOGAMICIN; IMMUNOGLOBULIN G ANTIBODY; INOTUZUMAB OZOGAMICIN; PENTETIC ACID; RESAZURIN; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN RECOGNITION; BINDING ASSAY; CANCER CHEMOTHERAPY; CELL ASSAY; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; IMMUNOASSAY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INTERFEROMETRY; INTERMETHOD COMPARISON; ISOTOPE LABELING; MASS SPECTROMETRY; MELANOMA; NONHUMAN; PHAGOCYTOSIS; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY;

ANIMALS; ANTIBODIES; CHEMISTRY TECHNIQUES, ANALYTICAL; CYTOLOGICAL TECHNIQUES; HUMANS; IMMUNOASSAY; IMMUNOCONJUGATES; PHARMACEUTICAL PREPARATIONS;

EID: 79953149070     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.30     Document Type: Review

References (149)

1. Reichert JM, Rosensweig CJ, Faden LB et al. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 23, 1073-1078 (2005). (Pubitemid 41486385)
2. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23, 1147-1157 (2005). (Pubitemid 41486396)
3. Reichert JM, Valge-Archer VE Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug Discov. 6, 349-356 (2007). (Pubitemid 46696550)
4. Carter PJ. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6, 343-357 (2006).
5. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drug as cancer therapeutics. Nat. Rev. Drug Discov. 5, 147-159 (2006).
6. Weiner LM. Building better magic bullets - improving unconjugated monoclonal antibody therapy for cancer. Nat. Rev. Cancer 7, 701-706 (2007). (Pubitemid 47327414)
7. Desjarlais JR, Lazar GA, Zhukovsky EA et al. Optimizing engagement of the immune system by antitumor antibodies: An engineer's perspective. Drug Discov. Today 12, 898-910 (2007). (Pubitemid 350052671)
8. Collins F. Has the revolution arrived? Nature 464, 674-675 (2010).
9. Venter C. Multiple personal genomes await. Nature 464,676-677 (2010).
10. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. The Cancer Journal 14, 154-168 (2008). n Discusses critical parameters for antibody-drug conjugate (ADC) development, especially from an antibody aspect.
11. Teicher BA. Antibody-drug conjugate targets. Current Cancer Drug Target 9, 982-1004 (2009). n Review article discussing the different proteins being targeted through ADCs. Extensive list of references.
12. Senter PD. Recent advancements in the use of antibody drug conjugates for cancer therapy. Current trends in monoclonal antibody development and manufacturing, Biotechnology: Pharmaceutical Aspects 309-322 (2010). n Review article discussing critical parameters for ADC development, especially from a drug and linker aspect. Extensive list of references.
13. Hughes B. Antibody-drug conjugates for cancer: Poised to deliver? Nature Rev. 9, 665-667 (2010).
14. Singh R, Erickson HK. Antibody-cytotoxic agent conjugates: Preparation and characterization. Therapeutic Antibodies: Methods and Protocols (Volume 525), Dimitrov A (Ed.). Humana press, 445-467 (2009).
15. Mascelli MA, Zhou H, Sweet R et al. Molecular, biologic and pharmacokinetic properties of monoclonal antibodies: Impact of these parameters on early clinical development. J. Clin. Pharmacol, 47, 553-565 (2007). (Pubitemid 46632148)
16. Sievers EL, Larson RA, Stadtmauer EA et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19, 3244-3254 (2001). (Pubitemid 32591442)
17. Mandler R, Kobayashi H, Hinson ER, Brechbiel MW, Waldmann TA. Herceptin®- gledanamycin immunoconjugates: Pharmacokinetics, biodistribution, and enhance antitumor activity. Cancer Res.64, 1460-1467 (2004).
18. Phillips GDL, Li G, Dugger DL et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68, 9280-9290 (2008).
19. Polson AG, Williams M, Gray AM et al. Anti-CD22-MCC-DM1: An antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma. Leukemia 24, 1566-1573 (2010).
20. Carter PJ, Presta L, Gorman CM et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl Acad. Sci. USA 89, 4285-4289 (1992).
21. Roguska MA, Petersen JT, Keddy CA et al. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc. Natl Acad. Sci. USA 91, 969-973 (1994). (Pubitemid 24048490)
22. McCafferty J, Griffiths A, Winter G et al. Phage antibodies: Filamentous phage displaying antibody variable domains. Nature 348, 552-554 (1990). (Pubitemid 120015109)
23. Bross PF, Beitz J, Chen G et al. Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7,1490-1496 (2001). (Pubitemid 32708610)
24. Hamann PR, Hinman LM, Hollander I et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody- clicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. 13, 47-58 (2002). (Pubitemid 34119634)
25. Dijoseph JF, Armellino DC, Boghaert ER et al. Antibody-targeted chemotherapy with CMC-544: A CD22-targeted immunoconjugate of calicheamicin for treatment of B-lymphoid malignancies. Blood 103, 1807-1814 (2004). n Investigative article describing the characterization of an anti-CD22 ADC. Implementation of various bioanalytical assays, including a conjugated antibody ELISA-based assay. (Pubitemid 38268977)
26. Larson RA, Sievers EL, Stadtmauer EA et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg®) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 92, 1442-1452 (2005). (Pubitemid 41356159)
27. Jedema I, Barge RM, van der Velden VH et al. Internalization and cell cycledependent killing of leukemia cells by gemtuzumab ozogamicin: Rational for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 18, 316-325 (2004). (Pubitemid 38240048)
28. Boghaert ER, Khandke K, Sridharan L et al. Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy. Int. J. Oncol. 28, 675-684 (2006). n Investigative article describing the characterization of an anti-5T4 ADC. Implementation of various bioanalytical assays, including a total antibody assay using surface plasmon resonance.
29. Widdison WC, Wilhelm SD, Cavanagh EE et al. Semisynthetic maytansine analogues for targeted treatment of cancer. J. Med. Chem. 49, 4392-4408 (2006). (Pubitemid 44036683)
30. Chari RVJ. Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc. Chem. Res. 41, 98-107 (2008).
31. Chari RVJ, Martell BA, Gross JL et al. Immunoconjugates containing novel maytansinoids: Promising anticancer drugs. Cancer Res. 52, 127-131 (1992).
32. Doronina SO, Toki BE, Torgov MY et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21, 778-754 (2003).
33. Doronina SO, Mendelsohn BA, Bovee TD et al. Enhance activity of monomethylauristatin F through monoclonal antibody delivery: Effect of linker technology on efficacy and toxicity. Bioconjug. Chem. 17, 114-124 (2006). n Investigative article describing the characterization of an anti-CD30 ADC. Implementation of various bioanalytical assays, including a total antibody assay using MS. (Pubitemid 43157592)
34. Erickson HK, Park PU, Widdison WC et al. Antibody-maytansinoid conjugates are activated in target cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 66, 4426-4433 (2006).
35. Sutherland MSK, Sanderson RJ, Gordon KA et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30- auristatin conjugates. J. Biol. Chem. 281, 10540-10547 (2006). (Pubitemid 43864594)
36. Ranson M, Sliwkowski MX. Perspective on anti-HER monoclonal antibodies. Oncology 63, 17-24 (2002).
37. Vogel CL, Burris HA, Limentani S et al. A Phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC) in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results Clin. Oncol. 27, 15s (2009) (Abstract 1017).
38. Pietersz GA, Rowland A, Smyth MJ et al. Chemoimmunoconjugates for the treatment of cancer. Adv. Immunol. 56, 301-387 (1994). (Pubitemid 24242227)
39. Trail PA, King HD, Dubowchik GM. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol. Immunother. 52, 328-337 (2003). (Pubitemid 36578026)
40. Trail PA, Willner D, Lasch SJ et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 261, 212-215 (1993). (Pubitemid 23265398)
41. Tolcher AW, Sugarman S, Gelmon KA et al. Randomized Phase II study of BR96- doxorubicin conjugate in patient with metastatic breast cancer. J. Clin. Oncol. 17, 478-484 (1999). (Pubitemid 29075231)
42. Saleh MN, Sugarman S, Murray J et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J. Clin. Oncol. 18, 2282-2292 (2000). (Pubitemid 30350221)
43. Lee MD, Manning JK, Williams DR et al. Calichemicins, a novel family of antitumor antibiotics. 3. Isolation, purification and characterization of calichemicins b1Br, g1Br, a2I, a3I, b1I, g1I, and D1I. J. Antibiotic. 42(7), 1070-87 (1989).
44. Myers AG, Cohen SB, Kwon BM. A Study of the reaction of calicheamicin g1 with glutathione in the presence of doublestranded DNA. J. Am. Chem. Soc. 116, 1255-1271 (1994).
45. Rinehart KL, Shield L S. Chemistry of the ansamycin antibiotics. Fortsch. Chem. Org. Naturst. 33, 231-307 (1976).
46. Suwanborirux K, Chang CJ, Spiut RW et al. Ansamitocin P-3, a maytansinoid, from Claopodium crispifolium and Anomodon attenuatus or associated actinomycetes. Experientia 46, 117 (1990).
47. Yu TW, Bai L, Clade D et al. The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum. Proc. Natl Acad. Sci. USA (12), 7968-7973 (2002). (Pubitemid 34650989)
48. Ikeyama S, Takeuchi M. Antitubulin activities of ansamitocins and maytansinoids. Biochem. Pharm. 30, 2421-25 (1981). (Pubitemid 11040760)
49. Issell BF, Crooke ST. Maytansine. Cancer Treat. Rev. 5, 199-207 (1978). (Pubitemid 9109517)
50. Petti GR, Kamano Y, Herald C et al. The isolation and structure of remarkable marine animal antineoplastic constituent: Dolostatin 10. J. Am. Chem. Soc. 109, 6883-6885 (1987). (Pubitemid 18036607)
51. Wu AM, Senter PD. Arming antibodies: Prospects and challenges for immunoconjugates. Nat. Biotechnol. 23(9), 1137-1146.(2005). (Pubitemid 41486395)
52. Walker MA, Dubowchik GM, Hofstead SJ et al. Synthesis of an immonoconjugate of camptothecin. Bioorg. Med. Chem. Lett. 12, 217-219 (2002).
53. Francisco JA, Cerveny CG, Meyer DL et al. cAC10-Val-CitMMAE, an anti-CD30- monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102, 1458-1465 (2003). (Pubitemid 36988057)
54. Ryan MC, Hering M, Peckham D et al. Antibody targeting of B-cell maturation antigen on malignant plasma cells. Mol. Cancer Ther. 6, 11, 3009-3018 (2007). (Pubitemid 350206779)
55. Benjamin D et al. Humanized anti-CD19 auristatin antibody-drug conjugates display potent antitumor activity in preclinical models of B-cell malignancies. Presented at: AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics. San Francisco, CA, USA 12-16 November. (Abstract B60).
56. Law L, Cerveny CG, Gordon KA et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin. Cancer Res. 10, 23, 7842-7851 (2004). (Pubitemid 39587522)
57. Law L, Gordon KA, Toki BE et al. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res. 66, 4, 2328-2337 (2006).
58. Polson AG, Calamine-Fenaux J, Chan P et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: Target and linker-drug selection. Cancer Res. 69, 2358-2364 (2009). n Investigative article describing the characterization of seven different ADCs. Implementation of pharmacokinetic ELISA-based assay.
59. Chen Y, Clark S, Wong T et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 67, 10, 4924-4932 (2007). (Pubitemid 46910200)
60. Junutula JR, Raab H, Clark S et al. W Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotech. 26, 925-932 (2008). n Investigative article describing a strategy to generate an anti-MUC16 ADC with engineered cysteine substitutions at specific positions for drug loading. Implementation of various bioanalytical methods.
61. Alley SC, Benjamin DR, Jeffrey SC et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug. Chem. 19, 759-765 (2008). (Pubitemid 351431408)
62. Lyons A, King DJ, Owens RJ et al. Sitespecific attachment to recombinant antibodies via introduced surface cysteine residues. Protein Eng. 3, 703-708 (1990). (Pubitemid 20284843)
63. Stimmel JB et al. Site-specific conjugation on serine right-arrow cysteine variant monoclonal antibodies. J. Biol. Chem. 275, 30445-30450 (2000).
64. Junutula JR, Bhakta S, Raab H et al. Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J. Immunol. Meth. 332, 41-52 (2008b).
65. Engvall E, Perlmann P. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry 8, 871-874 (1971).
66. Lequin RM. Enzyme immunoassay (EIA)/ enzyme-linked immunosorbent assay (ELISA). Clin. Chem. 51, 2415-2418 (2005). (Pubitemid 41692603)
67. Li W, Lam MS, Birkeland A. Cell-based assays for profiling activity and safety properties of cancer drugs. J. Parmacol. Toxicol. Meth. 54, 313-319 (2006). (Pubitemid 44636258)
68. Michelini E, Cevenini L, Mezzanotte L, Coppa A, Roda A. Cell-based assays: Fuelling drug discovery. Anal. Bioanal. Chem. 398, 227-238 (2010).
69. Tsukazaki K, Hayman EG, Rusolahti E. Effects of ricin A chain conjugates of monoclonal antibodies to human a-fetoprotein and placental alkaline phosphatase on antigen-producing tumor cells in culture. Cancer Res. 45, 1834-1838 (1985). (Pubitemid 15079146)
70. Stephan JP, Chan P, Lee C et al. Anti-CD22- MCC-DM1 and MC-MMAF conjugates: Impact of assay format on pharmacokinetic parameters determination. Bioconjug. Chem. 19, 1673-1683 (2008). n Investigative article describing various total and conjugated antibody ELISA-based assays for anti-CD22 ADCs. Extensive discussion about strengths and weaknesses of the different assay formats.
71. Lambert JM, Senter PD, Yay-Young A, Blättler WA, Gldmacher VS. Purified immunotoxins that are reactive with human lymphoid cells. J. Biol. Chem. 260, 12035-12041 (1985).
72. Sapra P, Stein R, Pickett J et al. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin. Cancer Res. 11, 5257-5264 (2005). (Pubitemid 41003714)
73. McDonagh CF, Turcott E, Westendorf L et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Engin. Design Select. 19, 299-307 (2006). n Investigative article describing a strategy to generate an anti-CD30 ADC with defined sites and stoichiometries of drug loading. Implementation of various bioanalytical methods. (Pubitemid 43999640)
74. Vater CA, Reid K, Bartle LM, Goldmacher VS. Characterization of antibody binding to cell surface antigens using a plasma membrane-bound plate assay. Anal. Biochem. 224, 39-50 (1995).
75. Boghaert ER, Khandke KM, Sridharan L et al. Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 microl). blood samples. Cancer Chemother. Pharmacol. 61, 1027-1035 (2008a). (Pubitemid 351423131)
76. Hamblett KJ, Senter PD, Chace DF et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10, 7063-7070 (2004). (Pubitemid 39383058)
77. Sun MMC, Beam KS, Cerveny CG et al. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconj. Chem. 16, 1282-1290 (2005). (Pubitemid 41368132)
78. Chari RV, Jackel KA, Bourret LA et al. Enhancement of the selectivity and antitumor efficacy of a CC-1065 analog through immunoconjugate formation. Cancer Res. 55, 4079-4084 (1995). n Investigative article describing the characterization of an anti-CD19 ADC. Implementation of various bioanalytical assays including a cell-based ELISA as total antibody assay.
79. Goldmacher VS, Tinnel NL, Nelson BC. Evidence that pinocytosis in lymphoid cells has a low capacity. J. Cell Bio. 102, 1312-1319 (1986). 80 Scott CF, Goldmacher VS, Lambert JM, (Pubitemid 16038075)
80. Chari RVJ, Bolender S, Gauthier MN, Blättler WA. The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin. Cancer Immunol. Immunother. 25, 31-40 (1987).
81. Sellers JR, Cook S, Goldmacher VS. A cytotoxicity assay utilizing a fluorescence dye that determines accurate surviving fractions of cells. J. Immunol. Methods 172, 255-264 (1994). (Pubitemid 24232715)
82. Senter PD, Saulnier MG, Schreiber GJ. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc. Natl Acad. Sci USA 85, 4842-4846 (1988).
83. Tai YT, Li XF, Catley L et al. Imonomodulatory drug lenalidomide (CC-5013, IMiD3). augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: Clinical implications. Cancer Research 65, 11712-11720 (2005). (Pubitemid 41821732)
84. Pirker R, FitzGerald DJP, Hamilton TC, Ozols RF, Willingham MC, Pastan I. Anti-transferrin receptor antibody linked to pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines. Cancer Research 45, 751-757 (1985). (Pubitemid 15161076)
85. DiJoseph JF, Dougher MM, Armellino DC et al. CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab. Cancer Immunol. Immunother. 56, 1107-1117 (2007). (Pubitemid 46675304)
86. Jeffrey SC, Torgov MY, Andreyka JB et al. Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates. J. Med. Chem. 48, 1344-1358 (2005). (Pubitemid 40364545)
87. Kim KM, McDonagh CF, Westendorf L et al. Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol. Cancer Ther. 7, 2486-2497 (2008). n Investigative article describing the characterization of an anti-CD30 ADC. Implementation of various bioanalytical assays, including a total antibody assay using radioactivity.
88. Anoopkumar-Dukie, Carey JB, Conere T, O'Sullivan E, Van Pelt FN, Allshire A. Resazurin assay of radiation response in cultured cells. Br. J. Radiol. 78, 945-947 (2005). (Pubitemid 41582247)
89. Francisco JA, Gilliland LK, Stebbins MR, Norris NA, Ledbetter JA, Siegall CB. Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cell expressing the CD40 antigen. Cancer Res. 55, 3099-3104 (1995).
90. Ingle GS, Pamela Chan P et al. High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate. Br. J. Haematol. 140, 46-58 (2007). n Investigative article describing the in vitro cell-based characterization of an anti-CD19 ADC. Implementation of various cell-based assays. (Pubitemid 350233252)
91. Hannah R. CellTiter-Glo™ luminescent cell viability assay: A sensitive and rapid method for determining cell viability. Promega Cell Notes 2, 11-13 (2001).
92. Franken NAP, Rodermond HM, Stap J, Haveman J, van Bree INITIAL. Clonogenic assay of cells in vitro. Nature Protocols 1, 2315-2319 (2006).
93. Herrera L, Farah RA, Pelligrini VA. Immonotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia 14, 853-858 (2000). (Pubitemid 30235063)
94. Daya S, Roberts M, Isherwood B et al.. Integrating an automated in vitro combination screening platform with live-cell and endpoint phenotypic assays to support the testing of drug combinations. SBS 16th Annual Conference & Exhibition. AZ, USA 11-15 April 2010.
95. Solly K, Wang X, Xu X, Strulovici B, Zheng W. Application of real-time cell electronic sensing (RT-CES). technology to cell-based assays. Assay Drug Dev. Technol. 2, 363-72 (2004). (Pubitemid 39276278)
96. Xing JZ, Zhu L, Jackson JA. Dynamic monitoring of cytotoxicity on microelectronic sensors. Chem. Res. Toxicol. 18, 154-61 (2005). (Pubitemid 40256233)
97. Goodman TT, Ng CP, Pun SH. 3-D tissue culture systems for the evaluation and optimization of nanoparticle-based drug carriers. Bioconjugate Chem. 19, 1951-1959 (2008).
98. Souza GR, Molina JR, Raphael RM et al. Tree-dimensional tissue culture based on magnetic cell levitation. Nat. Nanotech. 5, 291-296 (2010).
99. Austin CD, De Maziere AM, Pisacane PI et al. Endocytosis and sorting of ErbB2 and the site action of cancer therapeutics trastuzumab and geldanamycin. Mol. Bio. Cell 15, 5268-5282, (2004). (Pubitemid 39564723)
100. Hurwitz E, Levy R, Maron R et al. The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Res.35, 1175-1181 (1975).
101. Gilliland DG, Steplewski Z, Collier RJ et al. Biochemistry antibody-directed cytotoxic agents: Use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells (diphtheria toxin/ricin toxin/targeting agents/chemotherapy). Proc. Natl Acad. Sci. USA 77(8), 4539-4543 (1980). (Pubitemid 11236522)
102. Dowell JA, Korth-Bradley J, Liu H et al. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J. Clin. Pharmacol. 41, 1206-1214 (2001). (Pubitemid 32983219)
103. Pollack VA, Alvarez E, Tse KF et al. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE). targeting GPNMB. Cancer Chemother. Pharmacol. 60, 423-435 (2007). (Pubitemid 46944592)
104. Hwu P, Sznol M, Pavlick A et al. A Phase I/II study of CR011-vcMMAE, an antibody-drug conjugate, in patients with unresectable stage III or stage IV melanoma. Presented at: American Society of Clinical Oncology. Chicago, IL, USA, 30 May-3 June 2008.
105. Sznol M, Hamid O, Hwu P et al. Pharmacokinetics of CR011-vcMMAE, an antibody-drug conjugate, in a Phase I study of patients with advanced melanoma. Presented at: American Society of Clinical Oncology Orlando, FL, USA 29 May-2 June 2009. n Investigative article describing the characterization of an anti-GPNMB ADC. Implementation of various bioanalytical assays including a LC-MS-based free drug assay.
106. Hong K, Presta, LG, Lu Y et al. Simple quantitative live cell and anti-idiotypic based ELISA for humanized antibody direct to cell surface protein CD20. J. Immunol. Methods 294, 189-197 (2004). (Pubitemid 39626603)
107. Lu Y, Wong WL, Meng YG. A high throughput electrochemiluminescent cell-binding assay for therapeutic anti-CD20 antibody selection. J. Immunol. Methods 314, 74-79 (2006). (Pubitemid 44189428)
108. Henry MD, Wen S, Silva MD et al. A Prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Research 64, 7995-8001 (2004). (Pubitemid 39446934)
109. Tolcher AW, Ochoa L, Hammond LA et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: A Phase I, pharmacokinetic, and biologic correlative study. J. Clin. Oncol. 21, 211-222 (2003). n Investigative article describing the characterization of an anti-CanAg ADC. Implementation of various bioanalytical assays, including a conjugated antibody ELISA-based assay using an anti-idiotypic antibody as capture reagent. (Pubitemid 46606149)
110. Sanderson RJ, Hering MA, James SF et al. In vivo drug-linker stability of anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin. Cancer Res. 11, 843-852 (2005). (Pubitemid 40116913)
111. McDonagh CF, Kim KM, Turcott E et al. Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index. Mol. Cancer Ther. 7, 2913-2931 (2008).
112. Xie H Audette C Hoffee M et al. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J. Pharmacol. Exp. Ther. 308, 1073-1082 (2004). (Pubitemid 38263984)
113. Xu K, Saad O, Baudys J et al. Bioanalytical strategies for antibody drug conjugate (ADC). Biopharmaceutical development: Characterization of trastuzumab-MCC-DM1 in plasma by affinity mass spectrometry. Presented at: AAPS National Biotechnology Conference. 25 June, 2007.
114. Xu K, Liu L, Saad O et al. Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary LC-MS. Analytical Biochemistry doi :10.1016/j.ab.2011.01.004 (2011) (Epub ahead of print). n Investigative article describing a novel method with bead-based affinity capture and capillary LC-MS to allow direct measurement of drug release by quantifying dar distributions of the ADC in plasma/serum.
115. Engert A, Diehl V, Schnell R et al. A Phase-I study of an anti-CD25 ricin a-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood 89 (2).pp 403-410 (1997). (Pubitemid 27051674)
116. Schnell R, Vitetta E, Schindler JB et al. Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia 14, 129-135. (2000). (Pubitemid 30068384)
117. Kovtun YV, Audette CA, Ye Y et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 66, 3214-3221 (2006). n Investigative article describing the characterization of an anti-CanAg ADC. Implementation of various bioanalytical assays, including a conjugated antibody ELISA-based assay as well as a free drug assay.
118. Hsieh FY, Tengstrand E, Li LY et al. Toxicological protein biomarker analysis-an investigative one-week single dose intravenous infusion toxicity and toxicokinetic study in cynomolgus monkeys using an antibody- cytotoxic conjugate against ovarian cancer. Pharmaceut. Res. 25(6), 1309-1317 (2008).
119. Advani A, Coiffier B, Czuczman MS et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-hodgkin's lymphoma: Results of a Phase I study. J. Clin. Oncol. 28(12), 2085-2093 (2010).
120. Wang L, Amphlett G, Blattler WA et al. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci. 14, 2436-2446 (2005). (Pubitemid 41252812)
121. Alley SC, Zhang X, Okeley NM et al. The pharmacologic basis for antibody- auristatin conjugate activity. J. Pharmacol. Exp. Ther. 330, 932-938 (2009).
122. Oflazoglu E, Kissler KM, Sievers EL et al. Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumor activity in Hodgkin lymphoma. Br. J. Haematol. 142, 69-73 (2008). (Pubitemid 351783148)
123. Lu SX, Takach EJ, Solomon M et al. Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy. J. Pharmaceut. Sci. 94(4), 788-797 (2005). (Pubitemid 40577311)
124. Pendley C, Schantz A, Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr. Opin. Mol. Therap. 5, 172-179 (2003). (Pubitemid 36626459)
125. Liang M, Klakamp SL, Funelas C et al. Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms. ASSAY and Drug Development Technologies 5(5), 655-662 (2007).
126. Loyet KM, Deng R, Liang WC et al. Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study. J. Immunological Methods 345, 17-28 (2009).
127. Qiu ZJ, Ying Y, Fox M et al. A novel homogeneous biotin-digoxigenin based assay for the detection of human antitherapeutic antibodies in autoimmune serum. J. Immunological Methods 362, 101-111 (2010).
128. Peng K, Siradze K, Quarmby V et al. Clinical immunogenicity specificity assessments: A platform evaluation J. Pharmaceutical Biomedical Analysis 54, 629-635 (2011).
129. Dodge R, Daus C, Yaskanin D. Challenges in developing antidrug antibody screening assays. Bioanalysis 1, 699-704 (2009).
130. Stubenrauch K, Wessels U, Essig U et al. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from Cynomolgus monkeys after administration of human antibodies J. Pharmaceut. Biomed. Anal. 52, 249-254 (2010).
131. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Clinical response to adalimumab: Relationship to antiadalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 66, 921-926 (2007). (Pubitemid 46999794)
132. Mason S, La S, Mytych D, Swanson SJ, Ferbas J. Validation of the BIACORE 3000 platforms for the detection of antibodies against erythropoietic agents in human serum samples Curr. Med. Res. Opinion 19, 651-659 (2003). (Pubitemid 37288073)
133. Mire-Sluis AR, Barrett YC, Devanarayan V et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunological Methods 289, 1-16 (2004). (Pubitemid 38900899)
134. Wadhwa M, Thorpe R. Unwanted immunogenicity: Lessons learned and future challenges Bioanalysis 2, 1073-1084 (2010).
135. Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products, J. Pharmaceut. Biomed. Anal. 48, 1267-1281 (2008).
136. Swanson SJ, Chirmule N. Assessing specificity for immunogenicity assays. Bioanalysis 1, 611-617 (2009).
137. Gupta S, Indelicato SR, Jethwa V et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J. Immunol. Methods 321, 1-18 (2007). (Pubitemid 46454303)
138. Butterfield AM, Chain JS, Ackermann BL et al. Comparison of assay formats for drug-tolerant immunogenicity testing Bioanalysis 2, 1961-1969 (2010).
139. Swann PG, Tolnay M, Muthukkumar S et al. Considerations for the development of therapeutic monoclonal Antibodies. Curr. Opin. Immunol. 20, 493-499 (2008).
140. Kafi K, Betting DJ, Yamada RE et al. Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines. Molecular Immunology 46, 448-456 (2009).
141. Johnson DA, Barton RL, Fix DV et al. Induction of Immunogenicity of monoclonal antibodies by conjugation with drugs. Cancer Res. 51, 5774-5776 (1991).
142. Carrasco-Triguero M, Mahood C, Ruppel J et al. Overcoming soluble drug target interference in an immunogenicity screening assay for an antibody drug conjugate. Presented at: Biotherapeutic AAPS Annual Meeting. Atlanta, GA, USA 16-20 November 2008
143. Younes A, Bartlett NL, Leonard JP et al. brentuximab vedotin (SGN-35). for relapsed CD30-positive lymphomas N. Engl. J. Med. 363, 1812-1821 (2010).
144. Damle NK. Tumour-Targeted chemotherapy with immunoconjugates of calicheamicin. Expert Opin. Biol. Ther. 4(9), 1445-1452 (2004). (Pubitemid 39222977)
145. Kovtun YV, Goldmacher VS. Cell killing by antibody-drug conjugates. Cancer Letter 255, 232-240 (2007). (Pubitemid 47268641)
146. Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan MT. Nitrogen mustard therapy. JAMA 132, 26-32 (1946).
147. Joensuu H. Systemic chemotherapy for cancer: From weapon to treatment. Lancet Oncol. 9, 304 (2008). (Pubitemid 351722950)
148. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 332, 332-327 (1988).
149. Presta L. Engineering antibodies for therapy. Curr. Pharm. Biotechnol. 3, 237-256 (2002). (Pubitemid 34826556)